Resources

2 Resources for

technosphere

Mannkind entering fray over inhaled insulin market: MannKind Corp. marched into the American Diabetes Association's 65th annual Scientific Sessions last week looking a little bit like an underdog. But despite the fact that rival pharmaceutical companies are likely to beat MannKind to the market with competing insulin delivery products, the Valencia-based company has plenty of reasons...; Tags: American Diabetes Association, Exubera, FDA, Government, MannKind Corp., Technosphere; Research articles 2005-06-20
Pfizer Burns More Money on the Inhaled Insulin Bonfire: After burning $2.8 billion, Pfizer is throwing yet more money on the inhaled insulin bonfire. The company's announcement that it has a deal to switch former Exubera patients to MannKind's TechnoSphere is a real head-scratcher. One unanswered question is, exactly how many Exubera patients are there? Pfizer...; Tags: Pfizer Inc., MannKind, TechnoSphere, Jim Edwards; Blog posts 2008-09-18

MannKind Has Mountain to Climb If FDA Approves Afresa and TechnoSphere: MannKind is poised for a big leap -- if the FDA allows the company to sell its drug (delivered via its TechnoSphere inhaler, pictured) it can finally start earnng some revenues. Take a look at how high that leap will have to be. So far, MannKind's net loss to shareholders...; Tags: FDA, MannKind, Federal Government, Government, Jim Edwards; Blog posts 2009-07-09
MannKind Corp. Q1 2008 Earnings Call Transcript: Question-and-Answer SessionOperator Operator Instructions. Our first question is from Sa'ar Yaniv, JPMorgan. Sa'ar Yaniv - JPMorgan Thank you so much for taking my call. Can you discuss the carcinogenicity study such as the design and the study length? Alfred Mann Peter? Peter Richardson Yes. The first the carcinogenicity studies...; Tags: MannKind Corp.; Earnings calls 2008-05-05
Leerink Swann & Company Initiates Coverage of MannKind Corporation (NASDAQ: MNKD): Yesterday after the close, Senior Biotechnology Analyst, William Tanner, Ph.D., initiated coverage of MannKind Corporation (NASDAQ: MNKD) with an Outperform rating. His investment rating is based on his belief that MannKind's Technosphere, a potential best-in-class inhaled insulin product, positions it well for partnering opportunities.; Tags: Nasdaq Stock Market Inc.; Research articles 2005-10-13

Will FDA Approve MannKind's Insulin Inhaler?: MannKind stunned the diabetic community on Tuesday after reporting in a regulatory filing that it did not foresee entering into a co-marketing agreement for its lead product candidate, the inhaled insulin product AFRESA, before the end of 2009. Prudent business decision by management -- or a sign of Big Pharma's...; Tags: FDA, Patient, Insulin, MannKind, AFRESA, Federal Government, Government, David Phillips; Blog posts 2009-10-09
Dubai's Technosphere to simulate future climates: Tags: Dubai, construction, future climate; News items 2009-11-03